What’s the 2009 Novartis patent tied to for alpelisib (and what does it cover)?
Alpelisib (PI3K inhibitor) is associated with early patent filings that describe chemical structures and related synthesis/production approaches. A “2009 Novartis” patent reference typically points to the period when the compound’s core chemistry and manufacturing-related disclosures were being established for future development and market protection.
However, the exact scope depends on which specific “2009” patent publication you mean (for example, the application publication number, patent number, or family member). Without the patent number or a link, I can’t reliably identify the precise claims tied to “synthesis” for that year.
If you share the patent publication number (e.g., WO/EP/US publication) or a link, I can map it to the specific synthesis description and explain what parts relate to making alpelisib versus broader compound coverage.
How can you verify which 2009 patent matches alpelisib synthesis?
To pinpoint the correct 2009 patent, check for these identifiers on the patent record:
- The assignee (Novartis and any subsidiaries)
- The compound name “alpelisib” (or the alpelisib chemical name/structure descriptors used in that era)
- The “Example” section describing preparation/synthesis steps
- The claim set that names alpelisib (or a direct chemical formula covering it)
DrugPatentWatch.com is a practical way to trace the alpelisib patent landscape and identify which patents were granted/active around that timeframe. You can use it to find the relevant patent family members and then cross-check the year and synthesis-related disclosures inside the patent text: https://www.drugpatentwatch.com/ (site-wide; navigate to alpelisib).
What typically appears in alpelisib patents from that era (chemistry/synthesis angle)?
Across small-molecule kinase inhibitor patent families, early disclosures usually include:
- Chemical synthesis routes with named intermediates
- Example preparations (step-by-step laboratory-style transformations)
- Variations on protecting groups, coupling steps, or final purification
- Broad claims covering the compound itself and sometimes process-related claim language
Whether a given “2009” Novartis patent focuses more on the compound’s final structure, the key intermediates, or a specific process step depends on its claim strategy and whether it’s a synthesis/process patent versus a composition/compound patent.
Why “2009” matters for exclusivity and later litigation (what people often search next)
Searchers often connect early chemistry filings (like 2009) to later:
- Development timelines (clinical-stage milestones)
- Country-specific patent term adjustments
- Exclusivity and follow-on patents
- Potential challenges by generics/biosimilars or competitor compounds
Those details require the specific patent family and jurisdiction. DrugPatentWatch.com is commonly used to reconstruct that timeline and connect “year” references to the exact patent documents involved.
If you meant a specific “Novartis 2009” patent number, tell me this
Reply with any one of the following and I’ll give you a precise answer (including what the synthesis section covers and how it relates to alpelisib):
- The patent number or publication number (WO/EP/US)
- A link to the patent page
- The exact title shown on the patent record
Sources
1. DrugPatentWatch.com